Clinical trials: Sirolimus
Aging
Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer.
- Trial name
- NCT02874924
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Sickle Cell Disease, Hemoglobinopathies
Non-Myeloablative Conditioning and Bone Marrow Transplantation
Allogeneic blood or marrow transplantation (alloBMT) is a curative therapy for a variety of hematologic disorders, including sickle cell disease and thalassemia.
- Trial name
- NCT01850108
- Testing
- Thymoglobulin, Fludarabine, Cyclophosphamide (CTX)
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Sickle Cell Disease
Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor bone marrow transplant helps stop the growth of abnormal cells.
- Trial name
- NCT00489281
- Testing
- Cyclophosphamide, Fludarabine, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Systemic Lupus Erythematosus (SLE)
Prospective Study of Rapamycin for the Treatment of SLE
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown origin. It involves multiple organs including the joints, skin, kidneys and central nervous system.
- Trial name
- Rapamune (NCT00779194)
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Autosomal Dominant Polycystic Kidney Disease
Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
Currently the only approved use for rapamycin (sirolimus) is for immunosuppression after renal transplantation. This trial is designed to determine whether rapamycin is safe and effective treatment for patients with polycystic…
- Trial name
- NCT00920309
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Yale University
Lymphoma, Leukemia
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Background: Patients with cancers of the blood and immune system often benefit from transplants of stem cells from a genetically well-matched sibling.
- Conditions
- Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma
- Trial name
- NCT00074490
- Testing
- Rituximab, Fludarabine, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 442 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Cognitive Impairment, Mild, Alzheimer Disease
Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway
Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and investigate associated safety, tolerability…
- Trial name
- CARPE_DIEM (NCT04200911)
- Testing
- Rapamune
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Hematologic Malignancies
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served.
- Trial name
- NCT01203722
- Testing
- Fludarabine, Cytoxan, Total Body Irradiation
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Congenital Hemolytic Anemia, Sickle Cell Disease
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
People with severe congenital anemias, such as sickle cell anemia and beta-thalassemia, have been cured with bone marrow transplantation (BMT).
- Trial name
- NCT00061568
- Testing
- Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Aging, Epigenetics
Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock
Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic changes in the skin are elicited.
- Conditions
- Aging, Epigenetics, Inflammatory Mediators
- Trial name
- Topical-RAPA (NCT04608448)
- Testing
- Rapamycin Topical Ointment
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Glioma
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
The purpose of this research study is to learn if the study drug RAD001 can shrink or slow the growth of low-grade gliomas in children with Neurofibromatosis type 1 (NF1). Additionally, the safety of RAD001 will be studied.
- Trial name
- NFC-RAD001 (NCT01158651)
- Testing
- RAD001 (Everolimus)
- Where
- 12 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Alcohol Use Disorder, Alcohol Dependence
Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders
The purpose of this study is to examine the effects of rapamycin (sirolimus) versus a placebo, an inactive substance, on responses to alcohol cues in individuals with alcohol use disorder.
- Trial name
- NCT03732248
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Keloid
RAPA-Keloid Study of Keloid Regression
1. To test whether topical rapamycin regresses established keloids in humans by measuring surface area and height changes in the scar over time (6 months) 2.
- Trial name
- NCT04049552
- Testing
- Rapamycin 8% Ointment
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Non-Hodgkin's Lymphoma, Acute Leukemia in Remission
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
The purpose of this study is to find out if a combination of drugs (these are called: cyclophosphamide, sirolimus, and mycophenolate mofetil) will protect participants better against graft vs.
- Conditions
- Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis
- Trial name
- NCT03018223
- Testing
- Fludarabine, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Sickle Cell Disease, Thalassemia
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Background: Some sickle cell disease or beta-thalassemia can be cured with transplant. Researchers want to test a variation of transplant that uses low dose radiation and a combination of immunosuppressive drugs.
- Conditions
- Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
- Trial name
- NCT02105766
- Testing
- Alemtuzumab, Sirolimus, Cyclophosphamide
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Immunosuppression, Kidney Transplantation
HLA-Identical Sibling Renal Transplant Tolerance
The purpose of this study is to attempt to eliminate the necessity of immunosuppressive therapy for HLA-identical sibling Kidney Transplants, examine cellular chimerism of donor hematopoietic stem cell (DHSC) lineages for pairs…
- Conditions
- Immunosuppression, Kidney Transplantation, Graft Rejection
- Trial name
- NCT00619528
- Testing
- Infusion of Donor Hematopoietic Stem Cells and Campath-1H
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Northwestern University